Sakthimala Jagadeesan: Developing Therapeutics for Intestinal Disorder Pain

May 03, 2021 Posted by: Jill Jha Sakthimala Jagadeesan,  SDG3,  USA

Sakthimala: Our mission is to develop first-in-class oral small molecule therapeutics for treating barrier dysfunction diseases. Compromises in the epithelial barrier can lead to intestinal disorders, including inflammatory bowel disease (IBD). At Artus Therapeutics, Inc., we strongly believe our therapeutic approach for treating barrier dysfunction will address highly unmet needs, not just in IBD, but for other types of barrier dysfunctional diseases as well.

Katherine Venturo-Conerly: Supporting Mental Health Helps Kenyan Youth Thrive

Apr 30, 2021 Posted by: Jill Jha Katherine Venturo-Conerly,  SDG3,  USA

Katherine: Did you that about half of Kenyan high school students report high levels of depression or anxiety? However, there are very few mental health providers in Kenya, with only one to two psychiatrists per million citizens...At the Shamiri Institute, we aim to help adolescents in Kenya—and eventually other parts of Africa—thrive....

Daniele Foresti: Changing The Delivery of Drugs, One Drop at a Time

Apr 29, 2021 Posted by: Jill Jha Daniele Foresti,  SDG3,  SDG9,  USA

Daniele: Thanks for having me, Spiffy! You know, it is incredible what a new tool can enable for society. At AcousticaBio, we are harnessing the hidden potential of sound and microdroplets to make it easier to deliver novel, life-saving drugs....